Navigation Links
Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Date:10/4/2007

HOPKINTON, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Kenneth Rice, Jr., Executive Vice President and Chief Financial Officer of Alseres Pharmaceuticals, Inc., will be presenting a Company overview at the BIO Investor Forum 2007 Wednesday, October 10, 2007 at 5:15pm PDT in San Francisco, CA. This national investor forum sponsored by the Biotechnology Industry Organization is being held on October 9-11 at the Palace Hotel in San Francisco, CA. The presentation will be web cast live at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ALSE&item_id=16 and available on our investor web site for replay at http://www.alseres.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

The BIO Investor Forum is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" in 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy ... and the University Aviation Association (UAA), the unifying voice for collegiate aviation education, ... will encourage teamwork, competition, and success through a STEM-based education platform. , Much ...
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an ... Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to include allergy ... fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are escalating to ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line HeLa, established in ... data on cross-contamination of human cell lines with HeLa cells were published. Until recently, ... culture labs and is associated with dramatic consequences for research. , In this ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found a biomarker ... Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding ... men. ”The logical next step, in my estimation, was to scientifically track the evidence ...
Breaking Biology Technology:
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
(Date:3/20/2017)... 2017 PMD Healthcare announces the release of ... Management System (WMS), a remote, real-time lung health monitoring ... Healthcare is a Medical Device, Digital Health, and Chronic ... creating innovative solutions that empower people to improve their ... PMD developed the first ever personal spirometer, Spiro PD, ...
Breaking Biology News(10 mins):